Review Article|Articles in Press

Neoadjuvant Strategies for Esophageal Cancer

Role of Immunotherapy and Positron emission tomography (PET)-Guided Strategies
  • Author Footnotes
    1 These authors contributed equally to this work.
    Carly C. Barron
    1 These authors contributed equally to this work.
    Medical Oncology Training Program, OPG 7-7W259, University of Toronto, Toronto, Ontario, M5G 2M9, Canada

    Division of Medical Oncology, Princess Margaret Cancer Centre, OPG 7-715, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.
    Xin Wang
    1 These authors contributed equally to this work.
    Medical Oncology Training Program, OPG 7-7W259, University of Toronto, Toronto, Ontario, M5G 2M9, Canada

    Division of Medical Oncology, Princess Margaret Cancer Centre, OPG 7-715, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
    Search for articles by this author
  • Elena Elimova
    Corresponding author. Princess Margaret Cancer Centre,OPG 7-715, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada.
    Division of Medical Oncology, Princess Margaret Cancer Centre, OPG 7-715, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.
Published:February 26, 2023DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Thoracic Surgery Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sung H.
        • Ferlay J.
        • Siegel R.L.
        • et al.
        Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA A Cancer J Clin. 2021; 71: 209-249
        • Wang X.
        • Espin-Garcia O.
        • Jiang D.M.
        • et al.
        Impact of sites of metastatic dissemination on survival in advanced gastroesophageal adenocarcinoma.
        Oncology. 2022; 100: 439-448
        • Shapiro J.
        • van Lanschot JJB
        • Hulshof M.C.C.M.
        • et al.
        Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
        Lancet Oncol. 2015; 16: 1090-1098
        • Al-Batran S.-E.
        • Homann N.
        • Pauligk C.
        • et al.
        Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a ra.
        Lancet. 2019; 393: 1948-1957
        • Sun J.M.
        • Shen L.
        • Shah M.A.
        • et al.
        Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
        Lancet. 2021; 398: 759-771
        • de Geus-Oei L.F.
        • Slingerland M.
        PET-guided treatment algorithms in oesophageal cancer: the promise of the near future.
        J Thorac Dis. 2017; 9: 2736-2739
        • Thrift A.P.
        The epidemic of oesophageal carcinoma: where are we now?.
        Cancer Epidemiol. 2016; 41: 88-95
        • Morgan E.
        • Soerjomataram I.
        • Rumgay H.
        • et al.
        the global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020.
        Gastroenterology. 2022; 163: 649-658.e2
        • Alexandrou A.
        • Davis P.A.
        • Law S.
        • et al.
        Squamous cell carcinoma and adenocarcinoma of the lower third of the esophagus and gastric cardia: similarities and differences.
        Dis Esophagus. 2002; 15: 290-295
        • Rustgi A.
        • El-Serag H.B.
        Esophageal carcinoma.
        N Engl J Med. 2015; 372: 1472-1473
        • Kim J.
        • Bowlby R.
        • Mungall A.J.
        • et al.
        Integrated genomic characterization of oesophageal carcinoma.
        Nature. 2017; 541: 169-174
        • Davern M.
        • Donlon N.E.
        • Power R.
        • et al.
        The tumour immune microenvironment in oesophageal cancer.
        Br J Cancer. 2021; 125: 479-494
        • Eyck B.M.
        • van Lanschot JJB
        • Hulshof M.C.C.M.
        • et al.
        Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: The Randomized Controlled CROSS Trial.
        J Clin Oncol. 2021; 39: 1995-2004
        • Tepper J.
        • Krasna M.J.
        • Niedzwiecki D.
        • et al.
        Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
        J Clin Oncol. 2008; 26: 1086-1092
        • Iqbal S.
        • McDonough S.
        • Lenz H.J.
        • et al.
        Randomized, phase ii study prospectively evaluating treatment of metastatic esophageal, gastric, or gastroesophageal cancer by gene expression of ERCC1: SWOG S1201.
        J Clin Oncol. 2020; 38: 472-479
        • Yang H.
        • Liu H.
        • Chen Y.
        • et al.
        Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.
        JAMA Surg. 2021; 156: 721-729
        • Reynolds J.V.
        • Preston S.R.
        • O’Neill B.
        • et al.
        Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452).
        J Clin Oncol. 2021; 39: 4004
        • Hoeppner J.
        • Lordick F.
        • Brunner T.
        • et al.
        ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).
        BMC Cancer. 2016; 16: 503
        • Stahl M.
        • Stuschke M.
        • Lehmann N.
        • et al.
        Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
        J Clin Oncol. 2005; 23: 2310-2317
        • Bedenne L.
        • Michel P.
        • Bouché O.
        • et al.
        Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.
        J Clin Oncol. 2007; 25: 1160-1168
        • Kelly R.J.
        • Ajani J.A.
        • Kuzdzal J.
        • et al.
        Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer.
        N Engl J Med. 2021; 384: 1191-1203
        • Janjigian Y.Y.
        • Shitara K.
        • Moehler M.
        • et al.
        First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
        Lancet (London, England). 2021; 398: 27-40
        • Shah M.A.
        • Hofstetter W.L.
        • Kennedy E.B.
        • et al.
        Immunotherapy in patients with locally advanced esophageal carcinoma: ASCO treatment of locally advanced esophageal carcinoma guideline rapid recommendation update.
        J Clin Oncol. 2021; 39: 3182-3184
        • Eggermont A.M.M.
        • Blank C.U.
        • Mandala M.
        • et al.
        Adjuvant pembrolizumab versus placebo in resected stage III melanoma.
        N Engl J Med. 2018; 378: 1789-1801
        • Felip E.
        • Altorki N.
        • Zhou C.
        • et al.
        Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
        Lancet. 2021; 398: 1344-1357
        • Bajorin D.F.
        • Witjes J.A.
        • Gschwend J.E.
        • et al.
        Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma.
        N Engl J Med. 2021; 384: 2102-2114
        • Liu J.
        • Blake S.J.
        • Yong M.C.
        • et al.
        Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease.
        Cancer Discov. 2016; 6: 1382-1399
        • Boussiotis V.A.
        Molecular and biochemical aspects of the PD-1 checkpoint pathway.
        N Engl J Med. 2016; 375 (Longo DL, ed): 1767-1778
        • Sato H.
        • Niimi A.
        • Yasuhara T.
        • et al.
        DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells.
        Nat Commun. 2017; 8: 1751
        • Li C.
        • Zhao S.
        • Zheng Y.
        • et al.
        Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1).
        Eur J Cancer. 2021; 144: 232-241
        • Duan H.
        • Shao C.
        • Pan M.
        • et al.
        Neoadjuvant pembrolizumab and chemotherapy in resectable esophageal cancer: an Open-Label, Single-Arm Study (PEN-ICE).
        Front Immunol. 2022; 13 (849984)
        • Shah M.A.
        • Bennouna J.
        • Doi T.
        • et al.
        KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma.
        Future Oncol. 2021; 17: 1143-1153
        • Goodman K.A.
        • Xu R.
        • Chau I.
        • et al.
        SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy.
        J Clin Oncol. 2022; 40: TPS374
        • Chauvin J.M.
        • Zarour H.M.
        TIGIT in cancer immunotherapy.
        J Immunother Cancer. 2020; 8 (e000957)
        • Cho B.C.
        • Abreu D.R.
        • Hussein M.
        • et al.
        Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
        Lancet Oncol. 2022; 23: 781-792
        • Al-Batran S.-E.
        • Lorenzen S.
        • Thuss-Patience P.C.
        • et al.
        Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomize.
        J Clin Oncol. 2022; 40: 4003
        • Janjigian Y.Y.
        • Van Cutsem E.
        • Muro K.
        • et al.
        MATTERHORN: efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer—a randomized, double-blind, placebo-controlled, phase 3 study.
        J Clin Oncol. 2021; 39: TPS4151
        • Eads J.R.
        • Weitz M.
        • Gibson M.K.
        • et al.
        A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: A trial of the ECOG-ACRIN Cancer Research Group (EA2174).
        J Clin Oncol. 2020; 38: TPS4651
        • Terashima M.
        • Kim Y.-W.
        • Yeh T.-S.
        • et al.
        ATTRACTION-05 (ONO-4538-38/BMS CA209844): a randomized, multicenter, double-blind, placebo- controlled Phase 3 study of Nivolumab (Nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction (G/EGJ) cancer.
        Ann Oncol. 2017; 28: v266-v267
        • Bonneville R.
        • Krook M.A.
        • Kautto E.A.
        • et al.
        Landscape of microsatellite instability across 39 cancer types.
        JCO Precis Oncol. 2017; 2017
        • Vrána D.
        • Matzenauer M.
        • Neoral Č.
        • et al.
        From tumor immunology to immunotherapy in gastric and esophageal cancer.
        Int J Mol Sci. 2018; 20: 13
        • Pietrantonio F.
        • Miceli R.
        • Raimondi A.
        • et al.
        Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer.
        J Clin Oncol. 2019; 37: 3392-3400
        • André T.
        • Tougeron D.
        • Piessen G.
        • et al.
        Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
        J Clin Oncol. 2023; 41: 255-265
        • Chatterton B.E.
        • Ho Shon I.
        • Baldey A.
        • et al.
        Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study.
        Eur J Nucl Med Mol Imaging. 2009; 36: 354-361
        • You J.J.
        • Wong R.K.S.
        • Darling G.
        • et al.
        Clinical utility of 18F-Fluorodeoxyglucose positron emission tomography/computed tomography in the staging of patients with potentially resectable esophageal cancer.
        J Thorac Oncol. 2013; 8: 1563-1569
        • Manabe O.
        • Hattori N.
        • Itoh K.
        • et al.
        Value and limitation of 18F-FDG PET/CT in the staging of thoracic esophageal cancer.
        J Nucl Med. 2011; 52: 1842
        • Jiang C.
        • Chen Y.
        • Zhu Y.
        • et al.
        Systematic review and meta-analysis of the accuracy of 18F-FDG PET/CT for detection of regional lymph node metastasis in esophageal squamous cell carcinoma.
        J Thorac Dis. 2018; 10: 6066-6076
        • Cremonesi M.
        • Garibaldi C.
        • Timmerman R.
        • et al.
        Interim 18 F-FDG-PET/CT during chemo-radiotherapy in the management of oesophageal cancer patients. A systematic review.
        Radiother Oncol. 2017; 125: 200-212
        • Weber W.A.
        • Ott K.
        • Becker K.
        • et al.
        Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.
        J Clin Oncol. 2001; 19: 3058-3065
        • Ott K.
        • Weber W.A.
        • Lordick F.
        • et al.
        Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.
        J Clin Oncol. 2006; 24: 4692-4698
        • Lordick F.
        • Ott K.
        • Krause B.-J.
        • et al.
        PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
        Lancet Oncol. 2007; 8: 797-805
        • Meyer zum Büschenfelde C.
        • Herrmann K.
        • Schuster T.
        • et al.
        18 F-FDG PET–guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: The MUNICON II Trial.
        J Nucl Med. 2011; 52: 1189-1196
        • Barbour A.P.
        • Walpole E.T.
        • Mai G.T.
        • et al.
        Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II t.
        Ann Oncol. 2020; 31: 236-245
        • Lordick F.
        • Herrmann K.
        Metabolic response assessment and PET-guided treatment of esophageal cancer.
        Ann Oncol. 2020; 31: 163-164
        • Goodman K.A.
        • Ou F.-S.
        • Hall N.C.
        • et al.
        Randomized Phase II Study of PET response–adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) trial.
        J Clin Oncol. 2021; 39: 2803-2815
        • van Rossum P.S.N.
        • Fried D.V.
        • Zhang L.
        • et al.
        The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma.
        Eur J Nucl Med Mol Imaging. 2017; 44: 71-80
        • Elimova E.
        • Wang X.
        • Etchebehere E.
        • et al.
        18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients.
        Eur J Cancer. 2015; 51: 2545-2552
        • Simoni N.
        • Rossi G.
        • Benetti G.
        • et al.
        18F-FDG PET/CT metrics are correlated to the pathological response in esophageal cancer patients treated with induction chemotherapy followed by neoadjuvant chemo-radiotherapy.
        Front Oncol. 2020; 10: 1-11